Clinical characteristics of AML patients
| UPIN . | DX . | Source . | Blast (%) . | Status . | Cytogenetics . | Molecular mutations . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NPM1 . | FLT3 . | NRAS . | JAK . | Others . | (–)BI97D6 IC50 (nM) . | ||||||
| 1 | AML | PB | 55 | AML from MDS | del(5q), −7 | − | − | + | − | − | 6.1 |
| 2 | AML | PB | 82 | Newly diagnosed | inv(16) | U | U | U | U | U | 9.3 |
| 3 | AML | BM | 89 | Newly diagnosed | inv(16) | U | U | U | U | U | 11.3 |
| 4 | AML | PB | 98 | Post-SCT, refractory | — | − | + | − | − | − | 19.9 |
| 5 | AML | PB | 90 | Refractory | i(18)(q10) | − | − | − | U | − | 23.7 |
| 6 | AML | PB | 93 | Relapsed | Complex | + | + | − | − | FGFR2 | 24.7 |
| 7 | AML | PB | 69 | Refractory AMML | Diploid | − | − | − | − | − | 26.1 |
| 8 | AML | BM | 99 | Relapsed refractory | — | − | − | − | − | − | 27.5 |
| 9 | AML | PB | 93 | Refractory, relapsed after SCT | Complex | − | − | − | − | CEBPA | 27.8 |
| 10 | AML | PB | 66 | Refractory | — | − | − | − | U | − | 39.3 |
| 11 | AML | PB | 78 | Primary refractory | — | − | − | − | − | − | 41.6 |
| 12 | AML | PB | 87 | New therapy-related AML | t(9;11) | − | − | + | − | − | 42.3 |
| 13 | AML | PB | 85 | Primary refractory | — | − | − | − | − | − | 43.5 |
| 14 | AML | PB | 99 | AML from MDS, refractory | del(12p) | − | − | + | − | − | 43.6 |
| 15 | AML | PB | 81 | Relapsed | Diploid | + | − | − | − | DNMT3 | 47.8 |
| 16 | AML | PB | 99 | Relapsed refractory | inv(3) | − | + | − | − | IDH1 | 51.4 |
| 17 | AML | PB | 82 | Primary refractory | — | − | − | − | − | − | 69.2 |
| 18 | AML | BM | 77 | Post-SCT, relapsed | Diploid | + | − | − | − | DNMT3 | 99.9 |
| 19 | AML | PB | 74 | AML from MDS | N/A | − | − | − | − | − | 300.1 |
| UPIN . | DX . | Source . | Blast (%) . | Status . | Cytogenetics . | Molecular mutations . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NPM1 . | FLT3 . | NRAS . | JAK . | Others . | (–)BI97D6 IC50 (nM) . | ||||||
| 1 | AML | PB | 55 | AML from MDS | del(5q), −7 | − | − | + | − | − | 6.1 |
| 2 | AML | PB | 82 | Newly diagnosed | inv(16) | U | U | U | U | U | 9.3 |
| 3 | AML | BM | 89 | Newly diagnosed | inv(16) | U | U | U | U | U | 11.3 |
| 4 | AML | PB | 98 | Post-SCT, refractory | — | − | + | − | − | − | 19.9 |
| 5 | AML | PB | 90 | Refractory | i(18)(q10) | − | − | − | U | − | 23.7 |
| 6 | AML | PB | 93 | Relapsed | Complex | + | + | − | − | FGFR2 | 24.7 |
| 7 | AML | PB | 69 | Refractory AMML | Diploid | − | − | − | − | − | 26.1 |
| 8 | AML | BM | 99 | Relapsed refractory | — | − | − | − | − | − | 27.5 |
| 9 | AML | PB | 93 | Refractory, relapsed after SCT | Complex | − | − | − | − | CEBPA | 27.8 |
| 10 | AML | PB | 66 | Refractory | — | − | − | − | U | − | 39.3 |
| 11 | AML | PB | 78 | Primary refractory | — | − | − | − | − | − | 41.6 |
| 12 | AML | PB | 87 | New therapy-related AML | t(9;11) | − | − | + | − | − | 42.3 |
| 13 | AML | PB | 85 | Primary refractory | — | − | − | − | − | − | 43.5 |
| 14 | AML | PB | 99 | AML from MDS, refractory | del(12p) | − | − | + | − | − | 43.6 |
| 15 | AML | PB | 81 | Relapsed | Diploid | + | − | − | − | DNMT3 | 47.8 |
| 16 | AML | PB | 99 | Relapsed refractory | inv(3) | − | + | − | − | IDH1 | 51.4 |
| 17 | AML | PB | 82 | Primary refractory | — | − | − | − | − | − | 69.2 |
| 18 | AML | BM | 77 | Post-SCT, relapsed | Diploid | + | − | − | − | DNMT3 | 99.9 |
| 19 | AML | PB | 74 | AML from MDS | N/A | − | − | − | − | − | 300.1 |
DX, diagnosis; MDS, myelodysplastic syndrome; PB, peripheral blood; SCT, stem cell transplant; ; U, unknown; +, positive; −, none detected.